165 related articles for article (PubMed ID: 37712947)
1. A dual role for ERK-1/2 in the regulation of plasmin activity and cell migration in metastatic NSCLC-H1299 cells.
Zeitlmayr S; Cami D; Selmani B; Gudermann T; Breit A
Arch Toxicol; 2023 Dec; 97(12):3113-3128. PubMed ID: 37712947
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
3. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
[TBL] [Abstract][Full Text] [Related]
4. Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells.
Jakowlew SB; Mariano JM; You L
Growth Factors; 1997; 14(2-3):177-97. PubMed ID: 9255608
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.
Albo D; Berger DH; Vogel J; Tuszynski GP
J Gastrointest Surg; 1999; 3(4):411-7. PubMed ID: 10482694
[TBL] [Abstract][Full Text] [Related]
7. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
8. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.
Albo D; Arnoletti JP; Castiglioni A; Granick MS; Solomon MP; Rothman VL; Tuszynski GP
Biochem Biophys Res Commun; 1994 Sep; 203(2):857-65. PubMed ID: 8093068
[TBL] [Abstract][Full Text] [Related]
10. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.
Odekon LE; Blasi F; Rifkin DB
J Cell Physiol; 1994 Mar; 158(3):398-407. PubMed ID: 8126064
[TBL] [Abstract][Full Text] [Related]
11. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.
Sandra D; Radha M; Harishkumar M; Yuichi N; Sayuri O; Masugi M
Phytomedicine; 2010 Jan; 17(1):42-6. PubMed ID: 19640694
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
16. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment.
Wu CZ; Chu YC; Lai SW; Hsieh MS; Yadav VK; Fong IH; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen JS
Phytomedicine; 2022 Jun; 100():154062. PubMed ID: 35366491
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor.
Falcone DJ; McCaffrey TA; Haimovitz-Friedman A; Garcia M
J Cell Physiol; 1993 Jun; 155(3):595-605. PubMed ID: 7684044
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Hirashima Y; Kobayashi H; Suzuki M; Tanaka Y; Kanayama N; Terao T
J Biol Chem; 2003 Jul; 278(29):26793-802. PubMed ID: 12743121
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
